Clinical trial
Effect of Pegvisomant on GH/IGF-I Relationship in GHD
NCT00468624 · The Christie NHS Foundation Trust, Other · Terminated
Key facts
| NCT number | NCT00468624 |
|---|---|
| Title | Effect of Pegvisomant on GH/IGF-I Relationship in GHD |
| Official title | A Study of the Relationship Between Serum Growth Hormone (GH) and Insulin-Like Growth Factor One (IGF-I) in Patients With Severe Adult Growth Hormone Deficiency (AGHD) |
| Lead sponsor | The Christie NHS Foundation Trust, Other |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Severe Adult Growth Hormone Deficiency |
| Intervention type | Drug, Procedure |
| Interventions | pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks, GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo), blood sampling before and after pegvisomant/placebo, arginine stimulation test after each limb |
| Start date | Dec 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | May 3, 2007 |
| Last update posted | May 3, 2007 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: